People: Aileron Therapeutics Inc (ALRN.OQ)
14 Aug 2018
Mr. Manuel C. Aivado is Senior Vice President and Chief Medical Officer of the Company. Prior to joining Aileron, Dr. Aivado served as Taiho Oncology’s Vice President of Clinical Development and Pharmacovigilance. In that capacity, he built global clinical development capabilities, and led multiple drug programs ranging from phase 1 through phase 3, most prominently the global development of Teysuno® (S-1), TAS-102 and TAS-120. Prior to Taiho, Dr. Aivado held positions of increasing responsibility at GlaxoSmithKline, including as Senior Medical Director in the Clinical Development group, where he was involved in numerous drug programs including ofatumumab (Arzerra®), trametinib (Mekinist®), pazopanib (Votrient®), and eltrombopag (Promacta®). Prior to his industry experience, Dr. Aivado practiced ten years of clinical medicine in Germany. During his clinical career, he directed various molecular cancer research projects, which led him to be awarded the prestigious Dr. Mildred Scheel cancer research scholarship award in 2002. Dr. Aivado was previously an Instructor in Medicine at Beth Israel Deaconess Medical Center/Harvard Medical School, where he led the first ever-conducted proteomics research project in Myelodysplastic Syndromes (MDS). During his work in academia and in the pharmaceutical industry, Dr. Aivado’s work has culminated in more than 50 peer-reviewed papers, including research articles in Lancet, Nature Genetics and PNAS. Dr. Aivado is a member of the American Society of Hematology and a member of the American Society of Clinical Oncology. Dr. Aivado is a German Board-certified physician for Internal Medicine, Hematology, and Medical Oncology, and he earned an M.D. and Ph.D. from the Medical School of the University of Dusseldorf, in Germany.
|Total Annual Compensation,||--|
|Restricted Stock Awards,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|